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Abstract: Adenosine is readily available to the glandular epithelium of the stomach. Formed continuously
in intracellular and extracellular locations, it is notably produced from ATP released in enteric
cotransmission. Adenosine analogs modulate chloride secretion in gastric glands and activate acid
secretion in isolated parietal cells through A2B adenosine receptor (A2BR) binding. A functional link
between surface A2BR and adenosine deaminase (ADA) was found in parietal cells, but whether this
connection is a general feature of gastric mucosa cells is unknown. Here we examine whether A2BR
is expressed at the membrane of histamine-producing enterochromaffin-like (ECL) cells, the major
endocrine cell type in the oxyntic mucosa, and if so, whether it has a vicinity relationship with ADA.
We used a highly homogeneous population of rabbit ECL cells (size 7.5–10 µm) after purification by
elutriation centrifugation. The surface expression of A2BR and ADA proteins was assessed by flow
cytometry and confocal microscopy. Our findings demonstrate that A2BR and ADA are partially
coexpressed at the gastric ECL cell surface and that A2BR is functional, with regard to binding of
adenosine analogs and adenylate cyclase activation. The physiological relevance of A2BR and ADA
association in regulating histamine release is yet to be explained.
Keywords: adenosine; adenosine deaminase; G protein-coupled receptor; gastric neuroendocrine
cell; enterochromaffin-like (ECL) cell
1. Introduction
Adenosine (Ado) is a regulatory metabolite that modulates a broad spectrum of processes in many
cells of the gastrointestinal tract [1,2]. Ado is continuously produced in intracellular and extracellular
locations. In healthy, unstressed tissues, extracellular Ado has a very short-life due to a compensation
of concentrations between the extra and the intracellular compartments, which is mainly achieved
via equilibrative nucleoside transporters (ENTs) and a rapid metabolism. The Ado basal levels in
the interstitial fluid are between 30 and 300 nM [3]. However, under pathophysiological conditions,
such as metabolic stress or during inflammation-associated tissue hypoxia or ischemia, Ado generation
can exceed the removal capacity resulting in markedly increased extracellular concentrations [4].
Uncontrolled release from cells with damaged plasma membranes—such as that resulting from
mechanical stress or trauma—also provides large increases of extracellular purine nucleosides and
nucleotides (ATP levels in cells are typically 3–5 mM). In addition, ATP is a cotransmitter [2,5] and this
phenomenon is particularly evident in enteric nerves (excellent reviews can be found in references [2,6]).
Intrinsic enteric neurons release ATP, which, in addition to serving as a purinergic transmitter [7], can be
metabolized to Ado. Extracellular ATP can be ultimately converted into Ado by the sequential action of
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two families of enzymes: ectonucleoside triphosphate diphosphohydrolase (NTPDase or CD39) which
converts ATP to AMP, and ecto-5′-nucleotidase (CD73), which converts AMP to adenosine.
Structurally, Ado receptors are members of the seven transmembrane receptor superfamily and
they couple to G proteins [8]. Of the four subtypes of Ado receptors (A1, A2A, A2B and A3), the A2B
adenosine receptor (A2BR) still remains the most enigmatic subtype because of the relatively low
potency of Ado at this receptor (EC50 value of 24 µM) [9], and the very few specific agonists that
have been described so far. However, there is a growing interest in A2BR, as it has been found to
play a role in several diseases, including cardiovascular disease and cancer [10–13]. For example,
it was found that during inflammatory ischemia the local Ado level is elevated to levels sufficient
for A2BR activation [12] and that limited oxygen availability alters Ado signaling at the receptor
level, with A2BR being specifically overexpressed by the binding of the central regulator of oxygen
homeostasis hypoxia-inducible factor (HIF)-1α to its gene promoter [14,15]. This suggests that A2BR
may contribute to dampening inflammation during tissue hypoxia or to fine-tuning other tissue
responses when Ado concentration and the density of A2BR is abundant.
Gastric acid secretion is a tightly regulated process. The parietal cell of the gastric mucosa is
responsible for the release of hydrochloric acid (HCl) into the gastric lumen. This secretory process
is regulated by a highly coordinated interaction with other specialized cells of the stomach, mainly
the histamine-secreting enterochromaffin-like (ECL) cells in the body and fundus (the oxyntic area),
the gastrin-secreting G cells in the antrum that stimulate acid secretion [16,17], and the D cells in the
antrum, body, and fundus of the stomach secreting inhibitory somatostatin [18]. Globally, a collection of
neural stimuli (e.g., acetylcholine (ACh)) and endocrine and paracrine agents-acting directly at the parietal
cell or indirectly on the regulatory cells mentioned above-, as well as mechanical and chemical stimuli,
participate in the physiology of acid secretion (e.g., see reviews [2,17,19]). The primary stimulatory
processes are considered to be of histaminergic nature via Gs-coupled H2 receptor activation and of
cholinergic nature via activation of Gq-coupled muscarinic M3 receptors or receptors for gastrin [20],
but other actors are also on the stage. For example, we recently uncovered that gastric parietal cells also
possess functional A2BR receptors that couple to Gs to stimulate HCL production upon activation [21].
Adenosine deaminase (ADA) is the enzyme that degrades extracellular Ado by catalyzing the
irreversible deamination of Ado to inosine. Besides being present in the cytosol and the nucleus, ADA is
anchored to the cell surface and determined to be an ectoenzyme [22]. Four anchor proteins are known
for ADA: the Ado A1, A2A and A2B receptors and CD26 [23–26]. Surface ADA is a multifunctional
protein that, apart from degrading extracellular Ado, can act as a communication bridge between
cells and as a co-stimulating molecule in certain activation processes [23,27]. Several in depth studies
have considerably improved our understanding of the functional relationship between Ado receptors
and ADA [23–31]. Interestingly, A2BR was found to mediate ADA docking in CHO cells and Jurkat
cells [30], whereas, in dendritic cells, the complex A2BR-ADA was found to promote an immune
response triggered by a cell-adhesion co-stimulatory signal [23]. In a previous work, we showed that
A2BR is expressed in close apposition to ADA on the cell surface of gastric parietal cells, and that
this is especially important in cell-to-cell contact areas [31]. Hence, work in a variety of cell types and
cellular settings suggests that ADA may be a more general binding partner of A2BR than anticipated.
The parietal cell-ECL cell axis is the major governor of gastric acid secretion. ECL cells constitute
the predominant endocrine cell type in the acid-producing part of the stomach in mammals [32].
They respond to gastrin by releasing histamine and to somatostatin by reducing histamine
release [32,33], but the response of the ECL cell to Ado has not been explored. In this context, and using
a highly homogeneous population of ECL cells, we investigated whether the histamine-producing
ECL cells express functional A2BR in their surface and, if so, whether it colocalizes with ADA.
2. Results
ECL cells are predominantly located in the basal half of the acid-producing mucosa. In this work,
we isolated ECL cells from the body (corpus) region of the rabbit stomach by enzymatic digestion
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of the mucosa followed by separation of this specific cell population from other mucosal cells using
centrifugal elutriation [34] (Figure 1a). ECL cells were used without any prior stimulation, and their
size, cytoplasmic complexity and autofluorescence were characterized. The ECL cell is a small,
dense cell (8–10 µm) [35] that contains abundant granules and secretory vesicles storing histamine
and presents high cytoplasmic complexity [32,33,35]. Autofluorescence is a hallmark of the ECL cell
due to the presence of histamine in the secretory vesicles [36]. The particle size distribution analysis,
performed with Coulter Counter equipment, yielded that cells in our ECL populations consistently
had a diameter between 7.5 and 10 µm. As shown in the dot plot of the flow cytometry, two cellular
subpopulations can be differentiated in our preparations (Figure 1b). The X-axis represents frontal
dispersion of light (FS), which indicates cell size, and the Y-axis represents lateral dispersion (SS),
indicative of cell complexity. In Figure 1c, cell autofluorescence distribution is shown. Hence, the R1
subpopulation meets the criteria of ECL cells: size (7.5–10 µm), cytoplasmic complexity distribution
and autofluorescence. Because D cells and ECL cells have similar size and shape characteristics and D
cells lack autofluorescence [36], the R2 subpopulation may also contain contaminant D cells. The R1
subpopulation is predominant and accounts for more than 70% of the cells that were submitted to
immunostaining. It is important to mention that, to date, there are some reports supporting A1 [37]
and A2A [38] localization in D cells, but there is no such evidence for A3 and A2BR [39].
Figure 1. Scheme of the enterochromaffin-like (ECL) cell separation and flow cytometry characterization.
(a) ECL cells were isolated from the gastric mucosa of the rabbit stomach body region by centrifugal
elutriation; particle size distribution was analyzed using a Coulter Counter Multisizer II; (b) Spot diagram
of the flow cytometry analysis of a representative ECL cell preparation (n = 4). The X-axis represents
frontal dispersion of light (FS) and the Y-axis represents lateral dispersion (SS); (c) Autofluorescence in
R1 and R2 cell subpopulations (excitation at 488 nm and emission at 525 nm). The X-axis represents
fluorescence intensity (log FITC, arbitrary units) and the Y-axis represents the number of cells that
show fluorescence (events). R1 meets the characteristics of ECL cells: size (7.5–10 µm) and elevated
cytoplasmic complexity and autofluorescence [33].
With the aim of exploring whether gastric ECL cells expressed A2BR and ADA on their surface,
we performed immunostaining experiments using flow cytometry (Figure 2a) and confocal microscopy
(Figure 2b). In a previous study, we confirmed by western blotting experiments that the antibodies
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here used, that had been raised against the human proteins [28,30,40,41], recognized monospecifically
A2BR and ADA in rabbit tissue [31].Molecules 2017, 22, 625 4 of 12 
 
 
Figure 2. Immunodetection of cell surface adenosine deaminase (ADA) and A2BR in ECL cells by 
flow cytometry and confocal microscopy. (a) Monoparametric representation of fluorescence in R1 
and R2 cell subpopulations. The minimum number of cells used was 20,000. The X-axis represents 
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that show fluorescence (events). Top bottom: anti-A2BR-FITC fluorescence, anti-ADA-FITC fluorescence 
and nonspecific fluorescence. Histograms were analyzed with flowing software; (b) For confocal 
microscopy, cells were fixed and labeled with anti-A2BR-FITC (upper left image, green) and  
anti-ADA-TRITC (upper right image, red). The merge of the two images shows partial colocalization 
of cell surface A2BR and ADA (lower left image, yellow). The lower right image shows the confocal 
cytofluorogram in which yellow represents colocalization of the two proteins. 
Flow cytometry analysis revealed the distribution of ADA and A2BR in immunostained R1 and 
R2 cell subpopulations (Figure 2a). Cytometry was also performed using only the secondary antibody 
in order to assess the fluorescence intensity due to nonspecific binding; it accounts for 31% and 14% 
of the labeling for A2BR in R1 and R2 cells, and for 71% and 49% of the labeling for ADA in R1 and 
R2 cells, respectively. Those data were used to calculate the number of cells (%) that expressed A2BR 
or ADA with a fluorescence intensity higher than the nonspecific, basal fluorescence, which was 63% 
and 92% of A2BR-positive R1 and R2 cells, and 32% and 67% of ADA-positive R1 cells of R2 cells.  
The colocalization of A2BR and ADA at the ECL cell plasma membrane was studied by confocal 
microscopy of nonpermeabilized cell preparations (Figure 2b). ECL cells showed significant surface 
expression of A2BR (upper left image, green) and ADA (upper right image, red). The merge of both 
signals (lower left image) indicates that some ECL cells presented immunoreactivity only to A2BR 
(green) and others only to ADA (red), while others coexpressed the two antigens (yellow). The 
cytofluorogram in the fourth panel in Figure 2b shows that the colocalizing areas correspond to the 
pixels with the highest fluorescence intensity, indicating highly specific vicinity of A2BR and ADA, 
though there is a moderate degree of A2BR and ADA colocalization in ECL cells. 
Figure 2. Immunodetection of cell surface adenosine deaminase (ADA) and A2BR in ECL cells by
flow cytometry and confocal microscopy. (a) Monoparametric representation of fluorescence in R1 and
R2 cell subpopulations. The minimum number of cells used was 20,000. The X-axis represents FITC
fluorescence intensity (log FITC; arbitrary units) and the Y-axis represents the number of cells that show
fluorescence (events). T p bottom: anti-A2BR-FITC fluorescence, anti-ADA-FITC fluores ence and
nonspecifi flu rescence. Histograms were analyzed with flowing softwa e; (b) For confocal microscopy,
cells were fixed and labeled with anti-A2BR-FITC (upper left image, green) and anti-ADA-TRITC
(upper right image, red). The merge of the two images shows partial colocalization of cell surface
A2BR and ADA (lower left image, yellow). The lower right image shows the confocal cytofluorogram
in which yellow represents colocalization of the two proteins.
Flow cytometry analysis revealed the distribution of ADA and A2BR in immunostained R1 and
R2 cell subpopulations (Figure 2a). Cytometry was also performed using only the secondary antibody
in order to assess the fluorescence intensity due to nonspecific binding; it accounts for 31% and 14% of
the labeling for A2BR in R1 and R2 cells, and for 71% and 49% of the labeling for ADA in R1 and R2
cells, respectively. Those data were used to calculate the nu ber of cells (%) that expressed A2BR or
ADA with a fluorescence intensity higher than the nonspecific, basal fluorescence, which was 63% and
92% of A2BR-positive R1 and R2 cells, and 32% and 67% of ADA-positive R1 cells of R2 cells.
The colocalization of A2BR and ADA at the ECL cell plasma membrane was studied by confocal
microscopy of nonpermeabilized cell preparations (Figure 2b). ECL cells showed significant surface
expression of A2BR (upper left image, green) and ADA (upper right image, red). The merge of
both signals (low r left imag ) indicates that some ECL cells presented immunoreactivity only to
A2BR (green) and others only to ADA (red), while others coexpressed the two antigens (yellow).
The cytofluorogram in the fourth panel in Figure 2b shows that the colocalizing areas correspond to
the pixels with the highest fluorescence intensity, indicating highly specific vicinity of A2BR and ADA,
though there is a moderate degree of A2BR and ADA colocalization in ECL cells.
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A2BR is a low-affinity Ado receptor [8,9]. To investigate the functional significance of A2BR in ECL
cells, we analyzed the kinetic behavior of membranes purified by ultracentrifugation from ECL cells
towards [3H]5′-N-ethyl-carboxamido-adenosine (NECA). As shown in Figure 3a, the association of
50 nM [3H]NECA to membranes revealed that equilibrium was rapidly reached. Figure 3a also shows
the efficient displacement of radiolabeling by 50 µM unlabeled NECA. The association/dissociation
experimental data were compared with models of one or two binding site populations using GraphPad
software. The data best fitted a one site equation model (R2 = 0.88), giving a Kd of 103.8 ± 0.3 µM.
NECA is a nonspecific agonist for Ado receptors. However, the fact that data fit to a unique binding
site and that the obtained Kd value is in the range of those described for A2BR in many experimental
models [8,21,41–44], strongly suggests that A2BR is mediating NECA binding; it is several orders of
magnitude above those reported for the high-affinity receptors A1 and A2A and also for the so called
low-affinity A3 Ado receptor [9,43,44].
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Figure 3. Association-dissociation of [3H]NECA to ECL cell membranes from rabbit gastric mucosa,
and NECA-promoted effects in adenylate cyclase activity and Ca2+ levels. (a) After membranes
(0.5 mg protein/mL) were incubated with 50 nM [3H]NECA for 40 min, dissociation was provoked by
50 µM NECA. Values are the mean ± SEM of n = 3. Where absent, the error bar lies within the symbol;
(b) Adenylate cyclase activity was determined in cell embranes in the absenc (b sal) or presence
of 10−4 M NECA r 10−4 M forskolin. Data wer normalized with the basal value, that av raged
6.3 ± 2.8 pmol of cAMP produced/mg protein. Values are the mean ± SEM of n = 3. ** p < 0.01;
(c) A single ECL cell was sequentially challenged with 20 µM carbachol (CCh) and 10 µM NECA.
ATP (50 µM) acts as a positive control. Cytosolic calcium was measured by microfluorimetry, n > 15.
A2BR is k own to couple to Gs and Gq proteins [42,45]. Most A2B Ado receptors are coupled
to Gs proteins and activate adenylate cyclase, resulti g in the intracellular production of cAMP and
subsequent activation of PKA. However, activation of calcium-dependent mechanisms involving
the Gq family of proteins to activate PLC and increase intracellular Ca2+ has been reported in some
cell types [11,45]. To determine the signal transduction system operating in ECL cells, we evaluated
adenylate cyclase activity and mobilization of intracellular Ca2+ in response to A2BR activation.
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We confirmed that A2BR activation was coupled to Gs stimulation by direct measurement of the
cAMP-generating capacity of membranes isolated by ultracentrifugation from ECL cells (Figure 3b).
Control experiments in which membranes were treated with 10−4 M forskolin, a direct activator of
adenylate cyclase, resulted in high increases of cAMP production. In the same way, 10−4 M NECA
led to a moderate, but consistent and significant increase of about 45% in adenylate cyclase activity.
Similarly, 10−4 M 2-chloro-adenosine (2-CADO) also increased cAMP production (data not shown).
To test whether transduction by Gq was also involved in A2BR activation, cytosolic calcium waves
were recorded by microfluorimetry in individual ECL cells in response to various effectors (Figure 3c).
We observed the elevation of intracellular Ca2+ produced by carbachol (CCh), a muscarinic agonist
that has been reported to increase intracellular Ca2+ in ECL cells [46], manifested as an initial spike,
representing Ca2+ release from intracellular stores, followed by a lower level plateau caused by an
inward current of Ca2+. In contrast, no calcium mobilization occurred after challenging ECL cells
with NECA. As expected [47,48], not all the tested cells responded to CCh.
Collectively, our findings indicate that rabbit gastric ECL cells express A2BR and ADA at the cell
surface and that A2BR couples to Gs proteins, and not to Gi or Gq, upon agonist binding.
3. Discussion
The ECL cell of the oxyntic mucosa plays a critical role in the regulation of acid secretion through
the production and secretion of histamine. ECL cells respond to gastrin by releasing histamine
and to somatostatin by inhibiting histamine release. In this study, we have applied an elutriation
centrifugation procedure to obtain a cell suspension enriched in ECL cells from the body area of
the rabbit stomach mucosa. These cells are representative populations of native (nontransformed)
primary ECL cells at rest; therefore, it is possible to identify the surface receptors to which these
cells can putatively respond. We used specific antibodies in flow cytometry and confocal microscopy
experiments to assess the expression of A2BR, a receptor for Ado operating mainly via adenylate
cyclase activation, and ADA, the enzyme that is capable of inactivating endogenous Ado on the cell
surface and of binding Ado receptors, affecting their functionality [24,25]. We show for the first time
that ECL cells express the Gs-coupled A2BR as well as ADA on their surface.
The regulatory role of Ado in gastric acid secretion is inconclusive. Broadly speaking, it seems
evident that Ado has species-dependent actions on regulating acid secretion, which may be inhibitory
or stimulatory, and direct or indirect. Controversy mainly derives from the complexity of the network
that controls acid release, which makes it challenging to dissect the role of each individual component
(for a recent review, see Ref. [2]), and from the fact that Ado is always present within and outside cells.
This is exemplified in the perfused stomach of the A2A knockout mice, by showing that Ado has dual
actions on regulating the release of inhibitory somatostatin: stimulatory at high concentrations through A2A
receptor and inhibitory at low concentrations via A1 receptor activation, with no role for A2B and A3 [39].
In previous pharmacological studies we demonstrated that Ado analogs stimulate HCl secretion by acting
directly at the parietal cell through Gs-coupled A2BR binding [21]. Also in rabbit gastric mucosa, we show
here that most ECL cells express A2BR and some of them coexpress ADA, and that A2BR activation by the
Ado analog NECA triggers adenylate cyclase activation, which might affect the ECL cell function.
The main hormonal and paracrine stimulant of acid secretion is histamine released from ECL
cells, and the main hormonal stimulant of histamine release is gastrin secreted from G cells (Figure 4).
Gastrin acts as a ligand for the CCK-2 receptor on ECL cells, which activates PLC to induce a rise in
cytosolic Ca2+ resulting in exocytosis and the release of histamine [49]. Histamine release is evident
within 5 min after gastrin stimulation and the Ca2+ signal is virtually instantaneous [50]. Stimulation
of ECL cells by acetylcholine or the neuropeptide PACAP (pituitary adenylate cyclase-activating
polypeptide), a member of the vasoactive intestinal peptide family expressed in the enteric nerves,
also results in the release of histamine and is accompanied by a change in Ca2+ concentration [50].
Variations in cAMP levels do not seem to affect this secretion process; consequently, it seems unlikely
that A2BR activation can have a direct effect on exocytosis and the release of histamine from the
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secretory organelles in ECL cells. It was only in the rat that histamine secretion from ECL cells was
found to be activated by epinephrine and forskolin [48].
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exists that R2 fraction contains a mixture of histamine-depleted ECL cells and D cells. No evidence
exists of A2BR xpression in D cells [39], though there are reports supporting the presence of A1 [37]
and A2A [38]. What is remarkable in the current study is that most ECL cells (R1 cells) a positive to
A2BR and about half of them express ADA on their surface, indic ting that surface expression of A2BR
is nearly generalized on non timulated, resting ECL cells and higher than ADA expression.
In conclusion, w have identified A2BR as n Ado receptor that par ally interact with ADA at
the plasma membrane of ECL cells originating from the body of the rabbit stomach and that A2BR
couples t Gs upon activ tion. These findings raise the qu stion as to whether Ado itself has an impac
on the physiology of histamine secretion a d what the functi nal relevance of A2BR in ECL cells is. It is
nceivable that Ado might induce HDC promote activity and histamine synthesis by acting via A2BR
and denylat cyclase activation, in a simila fashio as PACAP. This is an important c nsideration for
future studies given th elevated local adenosine conce that are presum bly found during mucosal
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inflammation, which may hit histamine production in ECL cells and contribute to modulate acid
secretion in an effect complementary to that caused directly on the acid-secreting parietal cell.
4. Materials and Methods
4.1. Materials
[3H]5′-N-ethyl-carboxamido-adenosine (NECA) and [3H]cAMP were obtained from GE
Healthcare Life Sciences (Little Chalfont, UK), and ATP, NECA and CCh were obtained from
Sigma-Aldrich Química S.L. (Madrid, Spain).
4.2. Isolation and Enrichment of ECL Cells
Male and female New Zealand rabbits (2.5–4 kg bw) were used in accordance with the Spanish
(RD 1201/2005) and European (2003/65/CE Directive and 2007/526/CE Recommendation) guidelines
for the use of laboratory animals. Rabbits were housed in climate-controlled specific pathogen-free
facilities with a 12 h light/dark cycle, with free access to standard food and water. For each experiment,
two rabbits were used. The isolation of gastric mucosa cells by pronase and collagenase digestion of
the mucosa was carried out as described in previous works [21,31,54]. Briefly, after perfusion with
PBS, the stomach was removed and the fundic and antral regions were discarded. The corpus was
rinsed in PBS, the mucosa was separated and minced and the fragments were digested with pronase
and type I collagenase in oxygenated (95% O2 and 5% CO2) medium at 37 ◦C.
Cell separation was performed by counterflow elutriation at room temperature (~25 ◦C) in
a Beckman J-6M/E centrifuge equipped with a JE-6B rotor using a PBS buffer containing 2 mg/mL
glucose following the Sanders and Soll protocol [34] with minor modifications. The ECL cell fraction
was collected (500 mL) (at 2000 rpm and 37 mL/min) and washed (2400 rpm, 10 min). Size distribution
of harvested cells was analyzed in a Coulter-Counter Multisizer II (Hialeah, FL, USA). It was found
that 68.4% of cells in the final suspension had a size of 7.5–10 µm. Cell viability, as measured by the
Trypan blue exclusion test, averaged 96%.
4.3. Immunostaining Experiments: Flow Cytometry and Confocal Microscopy
The staining procedure was conducted exactly as described earlier [31] using anti-human A2BR [28]
and anti-human ADA [40]. Nonpermeabilized ECL cells were fixed in 2% (w/v) paraformaldehyde,
60 mM sucrose in PBS, pH 7.4, for 15 min at room temperature. After washing with 20 mM glycine
in PBS, cells were blocked with 1% BSA and incubated with anti-A2BR or anti-ADA antibodies and
a FITC-conjugated secondary antibody (Boehringer Mannheim, Barcelona, Spain). Primary antibodies
were provided by Prof. R. Franco (University of Barcelona, Barcelona, Spain).
Flow cytometry was performed with an EPICS Profile flow cytometer (Coulter Corporation,
Miami, FL, USA). The parameters used to select cell subpopulations for analysis were forward and
side light scattering. Cell sorting was performed using the EPICS Profile equipment and data were
analyzed using Flowing software (version 2.5.1; Turku Centre for Biotechnology, Turku, Finland).
For confocal microscopy analysis, cells were immunostained as with flow cytometry except
that a TRICT-conjugated secondary antibody (Boehringer Mannheim, Barcelona, Spain) was used
to visualize ADA. Cells were mounted with Immuno-Fluore mounting medium and scanned using
a Leica TCS 4D confocal scanning laser microscope adapted to an inverted Leitz DMIRBE microscope
(Leica Lasertechnik GmbH, Heidelberg, Germany). The colocalization analysis was performed by
means of Multi Color software (version 2.0; Leica Lasertechnik GmbH).
4.4. Isolation of ECL Cell Membranes
Plasma membranes were prepared as described previously [54]. ECL cells (60 × 106 cells/mL)
were homogenized with a Potter-Elvehjem homogenizer in ice-cold 20 mM Tris-HCl buffer, pH 7.4,
containing 250 mM sucrose, 0.5 mM EDTA, 0.54 mM dithiothreitol, 5 µg/mL leupeptin and 15.7 µg/mL
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benzamidine. The 700× g pellet was discarded and the supernatant was collected and placed on top
of a 47% sucrose solution and centrifuged (100,000× g, 4 ◦C, 45 min) in a swinging rotor. Plasma
membranes were then collected from the interphase and resuspended in 50 mM Tris-HCl buffer, pH 7.4
(buffer A) and washed (120,000× g, 4 ◦C, 20 min). Membranes were finally resuspended in buffer A
and stored at –80 ◦C until used. The protein concentration of the membranes was measured using the
method of Bradford [55].
4.5. Radioligand Binding Experiments
Binding assays were carried out as described by Casadó and co-workers [56]. Association
experiments were performed by incubating 50 nM [3H]NECA (850 nCi/nmol) with 0.5 mg membrane
protein/mL in buffer A at room temperature. Dissociation was induced by addding unlabeled NECA
after an association period of 40 min. At the times specified, free and membrane-bound radioligands
were quickly separated by vacuum filtration through Whatman GF/B filters previously soaked in 0.3%
polyethylenimine, pH 10, for 2 h. The filters were sequentially bathed in 6 mL of buffer A and placed
in 10 mL of a scintillation cocktail for radioactivity measurement. The experiment was repeated three
times and the assays were performed in duplicate.
4.6. Determination of Membrane Adenylate Cyclase Activity
Adenylate cyclase activity was determined in cell membranes by quantifying the cAMP generated
from ATP using a competitive protein binding procedure [57], as described previously [21]. In brief,
after membranes (0.8 mg protein/mL) were preincubated (5 min at 30 ◦C) in buffer A supplemented
with 5 mM Mg2Cl and 1 mM DTT, the reaction was initiated by adding 200 µM ATP and was stopped
10 min later. The samples were then centrifuged at 12,000 g for 2 min, and 50 µL supernatants were
taken for cAMP determination. To each well of a 96-well microplate, 50 µL of [3H]cAMP (54 Ci/mmol)
and 100 µL of 0.3 mg/mL bovine adrenal PKA were added in a total volume of 250 µL. A standard
curve of cAMP was included in each plate. Plates were incubated at 4 ◦C for 150 min and then freed
and PKA-bound [3H]cAMP were separated by vacuum filtration through Whatman GF/B filters using
a Skatron Micro 96 Harvester. Filters were washed twice with 3 mL of buffer A and placed afterwards
in 3 mL of a scintillation cocktail for radioactivity measurement. The experiment was repeated three
times and the assays were performed in quadruplicate.
4.7. Assessment of Calcium Mobilization in Individual Cells by Microfluorimetry
The cytosolic Ca2+ concentration was recorded in single cells using a multiple excitation
microfluorescence system (Cairn Research Ltd., Faversham, UK), as described in a previous work [21].
After three washes in medium DMEM:F12 (1:1, v/v), cells were seeded (1 × 106–2 × 106 cells) on
Matrigel-precoated coverslips and cultured for 1 h at 37 ◦C in 5% CO2 atmosphere in DMEM:F12
(1:1, v/v) supplemented with 15 mM HEPES, pH 7.4, 2 mM L-glutamine, 10 nM hydrocortisone,
1 mg/mL insulin, 0.1 mg/mL gentamicin, 0.5 µg/mL transferrin, 5 µg/mL sodium selenite, 10 mM
glucose, 5 µg/mL geneticin and 2 mg/mL BSA. Then, cells were washed and loaded with 5 µM
fura-2/AM for 60 min at 37 ◦C. Coverslips were placed in a superperfusion chamber of a Nikon
Diaphot microscope thermostatically controlled at 30 ◦C and the cells were excited alternatively at 340,
360 and 380 nm to monitor the fluorescence emitted at 510 nm. Control and calibration procedures as
well as the algorithms used to calculate the cytosolic Ca2+ concentration are described previously [58].
4.8. Statistical Analyses
All values are given as the mean ± SEM of 3–4 independent experiments. Differences between
two groups were assessed by unpaired Student’s two-tailed t-test using GraphPad Prism (version 5.02,
GraphPad software, La Jolla, CA, USA). Differences were considered significant at a value of p ≤ 0.05.
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